Description
TELMISIGN TRIO TABLET is a comprehensive antihypertensive solution that combines three pharmacologically complementary agents to provide optimal blood pressure control in patients who require multi-drug therapy.
Telmisartan: An angiotensin II receptor blocker (ARB) that relaxes blood vessels by preventing the action of a hormone that tightens blood vessels, thereby lowering blood pressure.
Amlodipine: A calcium channel blocker that widens blood vessels and improves blood flow by reducing the heart’s workload.
Hydrochlorothiazide (HCTZ): A thiazide diuretic that helps eliminate excess salt and water from the body to further reduce blood pressure and fluid retention.
This triple-combination therapy offers superior antihypertensive efficacy, especially for patients with:
Stage 2 or resistant hypertension
High cardiovascular risk profiles
Diabetes or chronic kidney disease
Inadequate response to monotherapy or dual therapy
Telmisartan blocks vasoconstrictor effects of angiotensin II.
Amlodipine inhibits calcium influx in vascular smooth muscle.
Hydrochlorothiazide promotes diuresis and sodium excretion.
Together, they provide a multi-targeted approach to control blood pressure, reduce fluid overload, improve heart function, and protect vital organs like the brain, kidneys, and heart.
Effective triple-drug therapy in one convenient daily dose
Improved patient compliance and therapeutic adherence
Fast-acting and long-lasting blood pressure control
Reduces the risk of stroke, heart attack, and kidney damage
Suitable for long-term cardiovascular disease prevention
Essential hypertension requiring three-drug combination therapy
Hypertension with target organ damage
Secondary prevention in patients with cardiovascular comorbidities
Taken once daily with or without food, as directed by a healthcare provider
Blood pressure should be monitored regularly during therapy
Dosage adjustments may be required in elderly patients or those with renal impairment
Not recommended during pregnancy or in patients with severe hepatic or renal dysfunction
Monitor electrolytes, kidney function, and blood pressure regularly
Avoid use with other potassium-sparing diuretics or potassium supplements
Use cautiously in patients with heart failure, diabetes, or gout
TELMISIGN TRIO TABLET is developed and manufactured under stringent quality control systems certified by WHO-GMP, ISO, and other international standards.
It is proudly represented and exported by BLUEPILL EXPRESS, a globally recognized third-party pharmaceutical manufacturer and supplier offering:
Global regulatory support
Timely and consistent delivery
High-quality finished formulations
Custom labelling and private branding services
BLUEPILL EXPRESS exports to over 40 countries, including regions in:
Asia
Africa
Latin America
Middle East
CIS countries
Europe
